3D-QSAR based pharmacophore modeling and virtual screening for identification of novel pteridine reductase inhibitors

被引:0
作者
Divya Dube
Vinita Periwal
Mukesh Kumar
Sujata Sharma
Tej P. Singh
Punit Kaur
机构
[1] All India Institute of Medical Sciences,Department of Biophysics
来源
Journal of Molecular Modeling | 2012年 / 18卷
关键词
Docking; Methotrexate; Neglected diseases; Pteridine reductase; Virtual screening;
D O I
暂无
中图分类号
学科分类号
摘要
Pteridine reductase is a promising target for development of novel therapeutic agents against Trypanosomatid parasites. A 3D-QSAR pharmacophore hypothesis has been generated for a series of L. major pteridine reductase inhibitors using Catalyst/HypoGen algorithm for identification of the chemical features that are responsible for the inhibitory activity. Four pharmacophore features, namely: two H-bond donors (D), one Hydrophobic aromatic (H) and one Ring aromatic (R) have been identified as key features involved in inhibitor-PTR1 interaction. These features are able to predict the activity of external test set of pteridine reductase inhibitors with a correlation coefficient (r) of 0.80. Based on the analysis of the best hypotheses, some potent Pteridine reductase inhibitors were screened out and predicted with anti-PTR1 activity. It turned out that the newly identified inhibitory molecules are at least 300 fold more potent than the current crop of existing inhibitors. Overall the current SAR study is an effort for elucidating quantitative structure-activity relationship for the PTR1 inhibitors. The results from the combined 3D-QSAR modeling and molecular docking approach have led to the prediction of new potent inhibitory scaffolds.
引用
收藏
页码:1701 / 1711
页数:10
相关论文
共 166 条
  • [1] Bello AR(1994)PTR1: a reductase mediating salvage of oxidized pteridines and methotrexate resistance in the protozoan parasite Leishmania major Proc Natl Acad Sci USA 91 11442-11446
  • [2] Nare B(1997)The roles of pteridine reductase 1 and dihydrofolate reductase-thymidylate synthase in pteridine metabolism in the protozoan parasite Leishmania major J Bio Chem 272 13883-13891
  • [3] Freedman D(1997)New approaches to Leishmania chemotherapy: pteridine reductase 1 (PTR1) as a target and modulator of antifolate sensitivity Parasitology 114 S101-110
  • [4] Hardy L(2004)Miltefosine for new world cutaneous leishmaniasis Clin Infect Dis 38 1266-1272
  • [5] Beverley SM(2007)Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis J Infect Disease 195 1846-1851
  • [6] Nare B(2006)Immunotherapy for drug-refractory mucosal leishmaniasis J Infect Disease 194 1151-1159
  • [7] Hardy LW(2010)Single-dose liposomal amphotericin B for visceral leishmaniasis in India N Engl J Med 362 504-512
  • [8] Beverley SM(2007)Injectable paromomycin for Visceral leishmaniasis in India N Engl J Med 356 2571-2581
  • [9] Nare B(2001)Pteridine reductase mechanism correlates pterin metabolism with drug resistance in trypanosomatid parasites Nat Struct Biol 8 521-525
  • [10] Luba J(2010)Trypanosoma brucei pteridine reductase 1 is essential for survival in vitro and for virulence in mice Mol Microbiol 77 658-671